Divis Laboratories Ltd (DIVISLAB) — shareholding pattern, promoter holding, financials and share price
About Divis Laboratories Ltd (DIVISLAB)
Divis Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as DIVISLAB and on the BSE under scrip code 532488. Its ISIN is INE361B01024.
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients [1]
Divi's Laboratories Limited is a vertically integrated pharmaceutical manufacturer and CDMO that produces Active Pharmaceutical Ingredients, intermediates, peptide fragments and nutraceutical ingredients, selling into over 100 countries with a dominant export mix and multi-site manufacturing footprint focused on generics, custom synthesis and nutraceuticals.
Financially, Q3 FY26 consolidated total income was ₹2,692 crore versus ₹2,401 crore year-ago, with profit before exceptional item and tax at ₹854 crore and reported profit after tax of ₹583 crore; nine-month revenue rose to ₹8,081 crore with constant-currency growth of 8.6% and material consumption improving from prior-year levels.
Listed peers in Pharmaceuticals: Torrent Pharmaceuticals Ltd, Cipla Ltd, Zydus Lifesciences Ltd, Lupin Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹6,832.3 a share on 10 Jul 2026, Divis Laboratories Ltd (DIVISLAB) was valued at a price-to-earnings ratio of 70.63x against an industry P/E of 36.41x and a price-to-book of 12.12x on a book value of ₹563.87 per share as of Mar 2025. Solomo computes return on equity of 17.16% and return on capital employed of 22.78% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 70.63x
- Industry P/E
- 36.41x
- P/B
- 12.12x
- EPS (TTM)
- ₹96.73
- Book value / share
- ₹563.87
- ROE
- 17.16%
- ROCE
- 22.78%
- ROA
- 15.17%
- Debt / equity
- 0x
- Dividend yield
- 0.44%
- EBITDA margin
- 36.69%
- 52-week range
- ₹5,637.5 – ₹6,963.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Divis Laboratories Ltd (DIVISLAB) reported revenue of ₹10,560 crore, net profit of ₹2,568 crore and earnings per share of ₹96.73. That compares with revenue of ₹9,360 crore and net profit of ₹2,191 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2,831 crore and net profit ₹751 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 8,960 | 7,768 | 7,845 | 9,360 | 10,560 |
| Net profit (₹ cr) | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 |
| EPS (₹) | 111.52 | 68.69 | 60.27 | 82.53 | 96.73 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.48% | 11.61% | 1.18% | 19.31% |
| Profit growth | 7.94% | 9.98% | -9.18% | 36.94% |
| Stock price CAGR | 20% | 9% | 26% | 7% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.88% of Divis Laboratories Ltd (DIVISLAB) (unchanged from the previous quarter), foreign institutional investors (FII) hold 20.2% and domestic institutional investors (DII) hold 19.38%. Market capitalisation was ₹1,81,376 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2003.
Largest disclosed public shareholders in Jun 2026: SBI MUTUAL FUND 3.9%, GOVERNMENT OF SINGAPORE 3.64%, Life Insurance Corporation of India 2.53%, HDFC MUTUAL FUND 2.07%, AXIS MUTUAL FUND TRUSTEE LIMITED 1.38%, NIPPON LIFE INDIA TRUSTEE LTD 1.29%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.88% | - | 20.2% | 19.38% | 48.12% |
| Mar 2026 | 51.88% | - | 20.29% | 19.22% | 48.12% |
| Dec 2025 | 51.88% | - | 20.08% | 19.28% | 48.12% |
| Sep 2025 | 51.89% | - | 19.39% | 19.76% | 48.11% |
| Jun 2025 | 51.89% | - | 19.74% | 19.05% | 48.11% |
| Mar 2025 | 51.89% | - | 18.01% | 20.71% | 48.11% |
| Dec 2024 | 51.89% | - | 17.99% | 20.54% | 48.11% |
| Sep 2024 | 51.89% | - | 17.25% | 21.06% | 48.11% |